Developmental Funds support strategic priorities of the Duke Cancer Institute by providing resources for new investigators, pilot projects, and development or application of new technologies. All Cancer Center members are eligible to apply for these funds and all funding decisions are made after formal peer review by the DCI Scientific Review Committee (or the Shared Resource Oversight Committee for new technologies for Shared Resources). The recruiting funds are made available at any time through the year to maintain optimal flexibility in faculty recruitment. These funds are used to help support high-priority, newly recruited DCI faculty investigators and represent an important component of their institutional start-up funds. Pilot project applications are formally solicited via Requests for Applications twice each year. All applications are reviewed by the Scientific Review Committee for scientific quality and impact as well as alignment with DCI priorities. The two co-chairs of the Scientific Review Committee, Drs. Chao and Counter, and the Chair of the Shared Resource Oversight Committee, Dr. Dewhirst, are members of the DCI Steering and Executive Committees, the former committee specifically charged with strategic oversight of the DCI; thus, Developmental Funds applications are reviewed with full consideration of DCI priorities. The Review Committee makes funding recommendations with final funding approval by the DCI Executive Director. One annual round of project Requests for Applications specifically solicits applications for innovative pilot projects and a second annual round specifically prioritizes inter-programmatic, intra-programmatic, and/or translational projects. Projects that would facilitate subsequent submission of multi-investigator grants (SPORES, Program Projects, etc.) are specifically encouraged. Typically, projects request approximately $50,000 per year and up to two years of support can be provided, though the second year of funding is dependent on approval of a second year of funding by the Scientific Review Committee which makes a determination of adequate progress during the first year of support by review of a formal progress report. During the funding period to date, $2M of CCSG support was distributed by this competitive application process to support the activities of more than 25 DCI investigators and over 40 pilot projects. Investigators receiving this support spanned all DCI Research Programs. In addition to the CCSG pilot funding support, these funds were supplemented by matching DCI funds and sometimes other sources to further leverage the CCSG support and provide a larger amount and broader distribution of support for these high priority activities. These investments resulted in approximately $41.5M of subsequent peer-reviewed and foundation support for DCI investigators. During the next funding period, plans are to continue to support new investigators, innovative high-priority pilot projects, and development or application of new technologies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-45
Application #
9620031
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications